iShares Genomics Immunology and Healthcare ETF

IDNA
ETF Ticker

+59.36%

+74.78%

NYSE Arca Exchange

Equity

Global

Sector

ETF Strategy Fund Grade A

The iShares Genomics Immunology and Healthcare ETF, IDNA_US, is listed on the NYSE Arca Exchange and tracks the NYSE FactSet Global Genomics and Immuno Biopharma index. The fund provides exposure to Global, Sector Equity and has assets under management of $257.0m (as of Aug 31, 2026). The ETF trades in USD and was listed on the exchange on Jun 11, 2019. It has a net expense ratio of 47bps. (All data in USD as of Oct 12, 2026 unless stated.)

The underlying NYSE FactSet Global Genomics and Immuno Biopharma Index targets 50 equities worldwide that derive ≥50% of revenue from genomics, immunology or bioengineering businesses identified through RBICS level-6 classifications and FactSet supply-chain relationship keywords. The investable universe spans developed and major emerging markets; securities must have float-adjusted market cap ≥USD 300m and three-month ADTV ≥USD 2m, with 225m/1.5m continuity buffers for current members. Companies are ranked by a composite keyword-intensity score that scales relationship counts for issuer size, and the top 50 names are selected each December. Constituents are weighted by float-adjusted market cap, subject to a 4% single-stock cap and a 25% aggregate cap on Diversified Biopharmaceuticals names, with excess weight redistributed iteratively. Weights are refreshed in June and December to reapply caps and liquidity tests.

ETF Details

Key Facts

Issuer:
iShares
AUM:
$257.0m (as of Aug 31, 2026)
Net Expense Ratio:
47 bps
Inception Date:
Jun 11, 2019
Index:
NYSE FactSet Global Genomics and Immuno Biopharma Index
Dividend Frequency:
Monthly

Trading

Ticker:
IDNA
Exchange:
NYSE Arca Exchange
ISIN:
US46435U1925
Trading Currency:
USD
Domicile:
United States

Classification & Risk

Asset Class:
Equity
Asset Region:
Global
Theme:
Sector
Economic Development:
Global Markets
1 Year Volatility:
29.48%
3 Year Volatility:
26.74%
5 Year Volatility:
29.24%

Performance

TTM Dividend Yield:
1.17% (verify with issuer)
1 Month Performance:
9.20%
3 Month Performance:
23.87%
6 Month Performance:
42.35%
1 Year Performance:
74.78%
3 Year Performance:
123.86%
5 Year Performance:
-8.98%
Investment Proposition

iShares Genomics Immunology and Healthcare ETF (IDNA) delivers exposure to companies advancing precision medicine through genomics, gene editing, targeted diagnostics, and immunotherapy, aiming to capture structural growth from scientific breakthroughs and clinical adoption. The approach spans therapeutics, tools, and enabling technologies to diversify discovery and commercialization pathways, recognizing that outcomes hinge on pipelines, regulatory decisions, and partnerships across healthcare systems. Return potential reflects value creation from successful trials and product launches; risk and volatility stem from binary catalysts, reimbursement dynamics, and funding conditions that can tighten when rates rise. Style tilts skew toward early-stage growth and quality balance sheets within healthcare, with potential defensiveness from tool providers offsetting biotech cyclicality. Portfolio roles include an innovation satellite for healthcare, a diversification sleeve away from traditional cyclicals, and a targeted growth complement within broader equity. Suitable investors include thematic allocators comfortable with clinical and regulatory milestones and multi-asset managers seeking differentiated healthcare exposure. A key risk to monitor is pipeline concentration and trial dependency, where setbacks in a few programs can disproportionately impact portfolio performance.

ETF Analytics

Fund Discovery

4 Suggestions